iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
October 14 2020 - 4:05PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, today
announced the appointment of Dr. Linda Armstrong to its Board of
Directors, effective immediately. Dr. Armstrong has also been
appointed as a member of iBio’s new Science & Technology
Committee, which shall be chaired by Dr. Philip Russell.
Dr. Armstrong is an accomplished
biopharmaceutical executive with more than 20 years of experience
in respiratory diseases and therapeutics. Since 2016, she has
served as the Global Head of the Respiratory Development Unit at
Novartis (SWX:NOVN), where she is responsible for the development
of therapies to treat patients with respiratory and allergic
conditions.
Dr. Armstrong served in a variety of roles at
Novartis since 2007, including the Head of Clinical Development
& Medical Affairs, Cell and Gene Therapy and Global Head of
Patient Safety. Prior to joining Novartis, she served as Medical
Safety Director and subsequently as Senior Director, Medical
Affairs at Pfizer, Inc. (NYSE:PFE). Dr. Armstrong also served as
Group Director, Respiratory Diseases at the Schering Plough
Research Institute. As a Board-Certified Pulmonologist and
Internist, Dr. Armstrong served on the faculty of New York
University Medical Center prior to joining Schering-Plough. She
received her medical degree from Yale University School of
Medicine, New Haven, Connecticut; and her Bachelor’s Degree from
Harvard University, Cambridge, Massachusetts.
“We are pleased to welcome Dr. Armstrong to our
Board and are confident that her deep experience in the development
and registration of biologics will be an asset to iBio,” said Tom
Isett, Chairman & CEO of iBio. “Moreover, as an expert
pulmonologist, we believe her guidance will be critical as we
progress the development of our respiratory disease portfolio,
which includes COVID-19 vaccine and therapeutic candidates, as well
as IBIO-100, which includes idiopathic pulmonary fibrosis as a
potential indication.”
Dr. Armstrong commented, “I am thrilled to join
iBio’s Board at such an exciting time in the Company’s development.
I am looking forward to supporting iBio as it advances an array of
respiratory disease biopharmaceuticals and other biologics.”
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming®
System combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. The Company’s
subsidiary, iBio CDMO LLC, provides FastPharming
Contract Development and Manufacturing Services. iBio’s
Glycaneering Development Service™
includes an array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products, which include IBIO-100 for the
treatment of fibrotic diseases, and vaccines for COVID-19 disease.
For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the expected
contribution of Dr. Armstrong. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the contribution of Dr. Armstrong to the
Board, the Company’s ability to obtain regulatory approvals for
commercialization of its product candidates, including its COVID-19
vaccines, or to comply with ongoing regulatory requirements,
regulatory limitations relating to its ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, its ability
to maintain its license agreements, the continued maintenance and
growth of its patent estate, its ability to establish and maintain
collaborations, its ability to obtain or maintain the capital or
grants necessary to fund its research and development activities,
competition, its ability to retain its key employees or maintain
its NYSE American listing, and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended June 30,
2020 and the Company’s subsequent filings with the SEC, subsequent
periodic reports on Forms 10-Q and 8-K. The information in this
release is provided only as of the date of this release, and we
undertake no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
Contact:
Stephen Kilmer iBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024